Skip to main content
Share Dataverse

Share this dataverse on your favorite social media networks.

Nighttime agitation in persons with Alzheimer’s disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of our limited knowledge of the etiology of nighttime agitation. We propose a clinical trial to better elucidate whether a sleep disorder, restless legs syndrome, may be a mechanism for nighttime agitation, and if treatment with gabapentin enacarbil (Horizant®) reduces nighttime agitation, improves sleep, reduces restless legs syndrome behaviors, and reduces antipsychotic medications.
Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Find Advanced Search

There are no dataverses within this dataverse. Please log in to see if you are able to add to it.

Add Data

You need to Log In to create a dataverse or add a dataset.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.

Contact Texas Data Repository Dataverse TDL Dataverse Support

Texas Data Repository Dataverse TDL Dataverse Support

Please fill this out to prove you are not a robot.

+ =
Send Message